| No. |
Drug (Description in trials) |
DrugBank |
KEGG DRUG * |
KEGG GENES * [Number of genes] |
KEGG PATHWAY [Number of pathways] |
Disease ID * [Number of diseases] |
| 1 |
Acetate |
Acetate |
- |
- |
- |
[40] 1, 2, 6, 10, 13, 35, 40, 46, 49, 51, 60, 64, 70, 71, 73, 75, 76, 78, 81, 83, 85, 86, 88, 90, 96, 97, 113, 145, 156, 162, 171, 206, 222, 224, 225, 235, 265, 288, 298, 299 |
| 2 |
Acipimox |
Acipimox |
D07190 |
- |
- |
[2] 78, 265 |
| 3 |
Acp-001 |
- |
- |
- |
- |
[1] 78 |
| 4 |
Acp-001 (transcon hgh) |
- |
- |
- |
- |
[1] 78 |
| 5 |
Aezs-130 (formerly ard-07) |
- |
- |
- |
- |
[1] 78 |
| 6 |
Albutropin |
- |
- |
- |
- |
[1] 78 |
| 7 |
Alrn-5281 0.015 mg/kg |
- |
- |
- |
- |
[1] 78 |
| 8 |
Alrn-5281 0.05 mg/kg |
- |
- |
- |
- |
[1] 78 |
| 9 |
Alrn-5281 0.15 mg/kg |
- |
- |
- |
- |
[1] 78 |
| 10 |
Altu-238 |
- |
- |
- |
- |
[1] 78 |
| 11 |
Amitriptyline |
Amitriptyline |
D00809, D07448 |
[2] SLC6A2, SLC6A4 |
[2] Serotonergic synapse, Synaptic vesicle cycle |
[3] 78, 226, 299 |
| 12 |
Amitriptyline, fluoxetine and tramadol alone (control group) |
Amitriptyline |
D00809, D07448 |
[2] SLC6A2, SLC6A4 |
[2] Serotonergic synapse, Synaptic vesicle cycle |
[1] 78 |
| 13 |
Anastrozole |
Anastrozole |
D00960 |
[1] CYP19A1 |
[3] Metabolic pathways, Ovarian steroidogenesis, Steroid hormone biosynthesis |
[3] 78, 86, 193 |
| 14 |
Arginin |
- |
- |
- |
- |
[1] 78 |
| 15 |
Arginine |
L-arginine |
D02982 |
- |
- |
[5] 67, 78, 113, 251, 299 |
| 16 |
Aricept |
Donepezil |
D00670, D07869 |
[1] ACHE |
[2] Cholinergic synapse, Glycerophospholipid metabolism |
[4] 6, 13, 78, 124 |
| 17 |
Arimidex (anastrozole) |
Anastrozole |
D00960 |
[1] CYP19A1 |
[3] Metabolic pathways, Ovarian steroidogenesis, Steroid hormone biosynthesis |
[1] 78 |
| 18 |
Arx201 |
Arx201 |
- |
- |
- |
[1] 78 |
| 19 |
Bplg-003 |
- |
- |
- |
- |
[1] 78 |
| 20 |
Caffeine |
Caffeine |
D00528, D01453 |
[11] ADORA1, ADORA2A, PDE1B, PDE2A, PDE3A, PDE3B, PDE4A, PDE4B, PDE4C, PDE4D, PDE5A |
[22] Alcoholism, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Glucagon signaling pathway, Insulin signaling pathway, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Olfactory transduction, Parathyroid hormone synthesis, secretion and action, Parkinson disease, Progesterone-mediated oocyte maturation, Purine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Taste transduction, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
[6] 2, 6, 46, 78, 96, 97 |
| 21 |
Catapresan |
- |
- |
- |
- |
[1] 78 |
| 22 |
Chemical conjugate of recombinant human growth hormone (rhgh) and human immunoglobulin g4 fragment (hmc001) |
Somatotropin |
D02691 |
[1] GHR |
[5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
[1] 78 |
| 23 |
Clonidin |
Clonidine |
D00281, D00604 |
[3] ADRA2A, ADRA2B, ADRA2C |
[2] Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway |
[1] 78 |
| 24 |
Clonidine |
Clonidine |
D00281, D00604 |
[3] ADRA2A, ADRA2B, ADRA2C |
[2] Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway |
[2] 6, 78 |
| 25 |
Clonidine hcl cf 0,150 mg, tabletten |
Clonidine |
D00281, D00604 |
[3] ADRA2A, ADRA2B, ADRA2C |
[2] Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway |
[1] 78 |
| 26 |
Clonidine hydrochloride |
Clonidine |
D00281, D00604 |
[3] ADRA2A, ADRA2B, ADRA2C |
[2] Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway |
[2] 6, 78 |
| 27 |
Corticotropin |
Corticotropin |
D00146 |
[1] MC2R |
[5] Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
[7] 2, 13, 46, 75, 78, 84, 222 |
| 28 |
Corticotropin releasing hormone |
Corticotropin |
D00146 |
[1] MC2R |
[5] Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
[1] 78 |
| 29 |
Daily rhgh |
Somatotropin |
D02691 |
[1] GHR |
[5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
[1] 78 |
| 30 |
Dextromethorphan |
Dextromethorphan |
D00848, D03742, D03744 |
[5] GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D |
[17] Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Rap1 signaling pathway, Ras signaling pathway, Systemic lupus erythematosus, cAMP signaling pathway |
[9] 2, 6, 8, 13, 46, 78, 96, 97, 156 |
| 31 |
Dextromethorphan and caffeine |
Dextromethorphan |
D00848, D03742, D03744 |
[5] GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D |
[17] Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Rap1 signaling pathway, Ras signaling pathway, Systemic lupus erythematosus, cAMP signaling pathway |
[1] 78 |
| 32 |
Donepezil |
Donepezil |
D00670, D07869 |
[1] ACHE |
[2] Cholinergic synapse, Glycerophospholipid metabolism |
[9] 5, 6, 13, 46, 78, 124, 127, 156, 206 |
| 33 |
Dose-establishing study 1 niacin 250mg |
Niacin |
D00049 |
- |
- |
[1] 78 |
| 34 |
Dose-establishing study 1 niacin 500mg |
Niacin |
D00049 |
- |
- |
[1] 78 |
| 35 |
Dose-establishing study 2 niacin 500mg |
Niacin |
D00049 |
- |
- |
[1] 78 |
| 36 |
Eutropin |
- |
- |
- |
- |
[2] 78, 193 |
| 37 |
Experimental: vrs-317 |
- |
- |
- |
- |
[1] 78 |
| 38 |
Fat diet |
- |
- |
- |
- |
[1] 78 |
| 39 |
Fluoxetine |
Fluoxetine |
D00326, D00823 |
[1] SLC6A4 |
[2] Serotonergic synapse, Synaptic vesicle cycle |
[4] 13, 17, 78, 86 |
| 40 |
Gelatin |
Gelatin |
D00115, D06892 |
- |
- |
[4] 47, 78, 97, 269 |
| 41 |
Genotropin |
Somatotropin |
D02691 |
[1] GHR |
[5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
[3] 13, 78, 193 |
| 42 |
Genotropin (pn-180,307) somatropin |
Somatotropin, Somatotropin |
D02691 |
[1] GHR |
[5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
[1] 78 |
| 43 |
Genotropin 12mg |
Somatotropin |
D02691 |
[1] GHR |
[5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
[3] 74, 75, 78 |
| 44 |
Genotropin 5 mg/ml |
Somatotropin |
D02691 |
[1] GHR |
[5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
[1] 78 |
| 45 |
Genotropin 5.3mg |
Somatotropin |
D02691 |
[1] GHR |
[5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
[3] 74, 75, 78 |
| 46 |
Genotropin mark vii pen |
Somatotropin |
D02691 |
[1] GHR |
[5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
[1] 78 |
| 47 |
Genotropin miniqu |
Somatotropin |
D02691 |
[1] GHR |
[5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
[3] 74, 75, 78 |
| 48 |
Genotropin miniquick |
- |
- |
- |
- |
[1] 78 |
| 49 |
Genotropin miniquick 0.2mg |
Somatotropin |
D02691 |
[1] GHR |
[5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
[3] 74, 75, 78 |
| 50 |
Genotropin miniquick 0.4mg |
Somatotropin |
D02691 |
[1] GHR |
[5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
[3] 74, 75, 78 |
| 51 |
Genotropin miniquick 0.5 mg, injection |
- |
- |
- |
- |
[1] 78 |
| 52 |
Genotropin miniquick 0.6mg |
Somatotropin |
D02691 |
[1] GHR |
[5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
[3] 74, 75, 78 |
| 53 |
Genotropin miniquick 0.8mg |
Somatotropin |
D02691 |
[1] GHR |
[5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
[3] 74, 75, 78 |
| 54 |
Genotropin miniquick 1.0mg |
Somatotropin |
D02691 |
[1] GHR |
[5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
[3] 74, 75, 78 |
| 55 |
Genotropin miniquick 1.2mg |
Somatotropin |
D02691 |
[1] GHR |
[5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
[3] 74, 75, 78 |
| 56 |
Genotropin, genotropin miniquick |
Somatotropin |
D02691 |
[1] GHR |
[5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
[1] 78 |
| 57 |
Genotropin® |
Somatotropin |
D02691 |
[1] GHR |
[5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
[1] 78 |
| 58 |
Gh substitution |
- |
- |
- |
- |
[1] 78 |
| 59 |
Ghrelin |
Lenomorelin |
- |
- |
- |
[3] 6, 78, 299 |
| 60 |
Ghrh |
Somatorelin |
D08523 |
[1] GHRHR |
[2] Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction |
[1] 78 |
| 61 |
Glucagon |
Glucagon |
D00116, D02118 |
[1] GCGR |
[2] Glucagon signaling pathway, Neuroactive ligand-receptor interaction |
[1] 78 |
| 62 |
Growth hormone |
Somatotropin |
D02691 |
[1] GHR |
[5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
[11] 2, 13, 19, 46, 78, 96, 191, 193, 195, 265, 299 |
| 63 |
Growth hormone (genotonorm® or omnitrope®) |
Somatotropin |
D02691 |
[1] GHR |
[5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
[2] 78, 193 |
| 64 |
Growth hormone (genotropin) |
Somatotropin |
D02691 |
[1] GHR |
[5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
[1] 78 |
| 65 |
Growth hormone (nutropin) |
Somatotropin |
D02691 |
[1] GHR |
[5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
[1] 78 |
| 66 |
Growth hormone (somatropin) |
Somatotropin |
D02691 |
[1] GHR |
[5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
[2] 2, 78 |
| 67 |
Growth hormone - lb03002 |
Somatotropin |
D02691 |
[1] GHR |
[5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
[1] 78 |
| 68 |
Growth hormone administration for 6 months |
Somatotropin |
D02691 |
[1] GHR |
[5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
[1] 78 |
| 69 |
Growth hormone releasing hormone (ghrh) 1-44 |
Somatotropin |
D02691 |
[1] GHR |
[5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
[1] 78 |
| 70 |
Growth hormone releasing hormone (ghrh) and arginine |
Somatotropin |
D02691 |
[1] GHR |
[5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
[1] 78 |
| 71 |
Growth hormone replacement therapy |
Somatotropin |
D02691 |
[1] GHR |
[5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
[1] 78 |
| 72 |
Growth hormone replacement therapy in growth hormone deficient patients only. |
Somatotropin |
D02691 |
[1] GHR |
[5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
[1] 78 |
| 73 |
Growth hormone, gh |
Somatotropin |
D02691 |
[1] GHR |
[5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
[1] 78 |
| 74 |
Growth hormone-releasing hormone |
Somatotropin |
D02691 |
[1] GHR |
[5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
[1] 78 |
| 75 |
Gx-h9 |
- |
- |
- |
- |
[1] 78 |
| 76 |
H01ac01 |
- |
- |
- |
- |
[1] 78 |
| 77 |
Hgh-hyfc, recombinant human growth hormone |
Somatotropin |
D02691 |
[1] GHR |
[5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
[1] 78 |
| 78 |
Hgh-viaderm™ system (hgh or somatropin) |
Somatotropin |
D02691 |
[1] GHR |
[5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
[1] 78 |
| 79 |
Hm10560a |
- |
- |
- |
- |
[1] 78 |
| 80 |
Human acylated ghrelin |
Lenomorelin |
- |
- |
- |
[1] 78 |
| 81 |
Human growth hormone |
Somatotropin |
D02691 |
[1] GHR |
[5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
[3] 78, 193, 265 |
| 82 |
Human growth hormone (1-134) |
Somatotropin |
D02691 |
[1] GHR |
[5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
[1] 78 |
| 83 |
Human serum albumin |
Human serum albumin |
D05424 |
- |
- |
[1] 78 |
| 84 |
Human serum albumin (hsa) fused to recombinant human growth hormone (hgh) |
Human serum albumin |
D05424 |
- |
- |
[1] 78 |
| 85 |
Human serum albumin (hsa) fused to somatropin |
Human serum albumin |
D05424 |
- |
- |
[1] 78 |
| 86 |
Humatrope |
Somatotropin |
D02691 |
[1] GHR |
[5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
[2] 78, 274 |
| 87 |
Hydrocortisone |
Hydrocortisone |
D00088 |
[1] NR3C1 |
[1] Neuroactive ligand-receptor interaction |
[8] 6, 53, 75, 78, 81, 83, 97, 299 |
| 88 |
Hydrocortisone takeda, tabletter |
Hydrocortisone |
D00088 |
[1] NR3C1 |
[1] Neuroactive ligand-receptor interaction |
[1] 78 |
| 89 |
Hydrocortone |
- |
- |
- |
- |
[1] 78 |
| 90 |
Hydrokortison glostrup 5 mg |
- |
- |
- |
- |
[1] 78 |
| 91 |
Increlex |
Mecasermin |
D03297, D04870 |
[2] GHR, IGF1R |
[33] AMPK signaling pathway, Adherens junction, Autophagy - animal, Breast cancer, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endocytosis, Focal adhesion, FoxO signaling pathway, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, JAK-STAT signaling pathway, Long-term depression, Longevity regulating pathway, Longevity regulating pathway - multiple species, MAPK signaling pathway, Melanoma, Neuroactive ligand-receptor interaction, Oocyte meiosis, Ovarian steroidogenesis, PI3K-Akt signaling pathway, Pathways in cancer, Progesterone-mediated oocyte maturation, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Signaling pathways regulating pluripotency of stem cells, Transcriptional misregulation in cancer, mTOR signaling pathway |
[3] 65, 78, 96 |
| 92 |
Increlex 10 mg/ml |
Mecasermin |
D03297, D04870 |
[2] GHR, IGF1R |
[33] AMPK signaling pathway, Adherens junction, Autophagy - animal, Breast cancer, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endocytosis, Focal adhesion, FoxO signaling pathway, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, JAK-STAT signaling pathway, Long-term depression, Longevity regulating pathway, Longevity regulating pathway - multiple species, MAPK signaling pathway, Melanoma, Neuroactive ligand-receptor interaction, Oocyte meiosis, Ovarian steroidogenesis, PI3K-Akt signaling pathway, Pathways in cancer, Progesterone-mediated oocyte maturation, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Signaling pathways regulating pluripotency of stem cells, Transcriptional misregulation in cancer, mTOR signaling pathway |
[1] 78 |
| 93 |
Insulin |
- |
- |
- |
- |
[5] 13, 46, 75, 78, 299 |
| 94 |
Jintropin aq |
- |
- |
- |
- |
[1] 78 |
| 95 |
L-arg |
L-arginine |
D02982 |
- |
- |
[1] 78 |
| 96 |
L-arg+ghrh |
L-arginine |
D02982 |
- |
- |
[1] 78 |
| 97 |
L-arginine |
L-arginine |
D02982 |
- |
- |
[4] 67, 78, 113, 299 |
| 98 |
Lb03002 |
- |
- |
- |
- |
[1] 78 |
| 99 |
Levothyroxine |
Levothyroxine |
D01010, D08125 |
[2] THRA, THRB |
[2] Neuroactive ligand-receptor interaction, Thyroid hormone signaling pathway |
[2] 49, 78 |
| 100 |
Macimorelin |
Macimorelin |
D10563 |
[1] GHSR |
[3] Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
[1] 78 |
| 101 |
Macimorelin acetate |
Macimorelin |
D10563 |
[1] GHSR |
[3] Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
[1] 78 |
| 102 |
Macrilen |
Macimorelin |
D10563 |
[1] GHSR |
[3] Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
[1] 78 |
| 103 |
Mecasermin |
Mecasermin |
D03297, D04870 |
[2] GHR, IGF1R |
[33] AMPK signaling pathway, Adherens junction, Autophagy - animal, Breast cancer, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endocytosis, Focal adhesion, FoxO signaling pathway, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, JAK-STAT signaling pathway, Long-term depression, Longevity regulating pathway, Longevity regulating pathway - multiple species, MAPK signaling pathway, Melanoma, Neuroactive ligand-receptor interaction, Oocyte meiosis, Ovarian steroidogenesis, PI3K-Akt signaling pathway, Pathways in cancer, Progesterone-mediated oocyte maturation, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Signaling pathways regulating pluripotency of stem cells, Transcriptional misregulation in cancer, mTOR signaling pathway |
[5] 78, 96, 168, 265, 299 |
| 104 |
Mod-4023 |
- |
- |
- |
- |
[1] 78 |
| 105 |
Mod-4023 (long-acting modified r-hgh) |
- |
- |
- |
- |
[1] 78 |
| 106 |
Niacin |
Niacin |
D00049 |
- |
- |
[3] 6, 78, 265 |
| 107 |
Niacin first |
Niacin |
D00049 |
- |
- |
[1] 78 |
| 108 |
Nn8630 |
- |
- |
- |
- |
[1] 78 |
| 109 |
Nnc 126-0083 |
- |
- |
- |
- |
[1] 78 |
| 110 |
Nnc0195-0092 |
Somapacitan |
D11194 |
[1] GHR |
[5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
[1] 78 |
| 111 |
Nnc0195-0092 10 mg/1.5 ml pds290-10 |
Somapacitan |
D11194 |
[1] GHR |
[5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
[1] 78 |
| 112 |
Nnc0195-0092 15 mg/1.5 ml pds290-15 |
Somapacitan |
D11194 |
[1] GHR |
[5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
[1] 78 |
| 113 |
Nnc0195-0092 5 mg/1.5 ml pds290-10 |
Somapacitan |
D11194 |
[1] GHR |
[5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
[1] 78 |
| 114 |
Nnc0195-0092 dp 6.7 mg ml 3 ml cartridge |
Somapacitan |
D11194 |
[1] GHR |
[5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
[1] 78 |
| 115 |
Nnc0195-0092 pds290 10 mg-1.5 ml |
Somapacitan |
D11194 |
[1] GHR |
[5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
[1] 78 |
| 116 |
Nnc0195-0092 pds290 10 mg/1.5 ml |
Somapacitan |
D11194 |
[1] GHR |
[5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
[1] 78 |
| 117 |
None |
- |
- |
- |
- |
[8] 46, 78, 84, 96, 160, 161, 171, 299 |
| 118 |
Norditropin |
Somatotropin |
D02691 |
[1] GHR |
[5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
[1] 78 |
| 119 |
Norditropin flexpro 10 mg |
Somatotropin |
D02691 |
[1] GHR |
[5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
[1] 78 |
| 120 |
Norditropin flexpro 10 mg/1.5 ml |
Somatotropin |
D02691 |
[1] GHR |
[5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
[1] 78 |
| 121 |
Norditropin growth hormone |
Somatotropin |
D02691 |
[1] GHR |
[5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
[1] 78 |
| 122 |
Norditropin nordiflex® |
- |
- |
- |
- |
[1] 78 |
| 123 |
Norditropin nordiflex® 10 mg/1.5 ml |
Somatotropin |
D02691 |
[1] GHR |
[5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
[1] 78 |
| 124 |
Norditropin nordiflex® 10mg/1.5 ml |
Somatotropin |
D02691 |
[1] GHR |
[5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
[1] 78 |
| 125 |
Norditropin simplex |
Somatotropin |
D02691 |
[1] GHR |
[5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
[1] 78 |
| 126 |
Norditropin simplexx |
Somatotropin |
D02691 |
[1] GHR |
[5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
[4] 3, 78, 193, 195 |
| 127 |
Norditropin simplexx (5mg/1,5 ml) (inn:somatropin) |
Somatotropin |
D02691 |
[1] GHR |
[5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
[1] 78 |
| 128 |
Norditropin simplexx (growth hormone) |
Somatotropin |
D02691 |
[1] GHR |
[5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
[1] 78 |
| 129 |
Norditropin simplexx 10 mg |
Somatotropin |
D02691 |
[1] GHR |
[5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
[1] 78 |
| 130 |
Norditropin simplexx 5mg/1.5ml |
Somatotropin |
D02691 |
[1] GHR |
[5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
[1] 78 |
| 131 |
Norditropin® |
- |
- |
- |
- |
[1] 78 |
| 132 |
Norditropin® flexpro® |
- |
- |
- |
- |
[1] 78 |
| 133 |
Norditropin® flexpro® pen |
- |
- |
- |
- |
[1] 78 |
| 134 |
Nutritional supplementation standardized formula |
- |
- |
- |
- |
[1] 78 |
| 135 |
Nutropin |
Somatotropin |
D02691 |
[1] GHR |
[5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
[2] 78, 274 |
| 136 |
Nutropin aq |
- |
- |
- |
- |
[4] 78, 134, 193, 299 |
| 137 |
Nutropinaq |
Somatotropin |
D02691 |
[1] GHR |
[5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
[1] 78 |
| 138 |
Nutropinaq 10 mg/2 ml |
Somatotropin |
D02691 |
[1] GHR |
[5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
[1] 78 |
| 139 |
Nutropinaq 10 mg/2 ml (30 ui) |
Somatotropin |
D02691 |
[1] GHR |
[5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
[1] 78 |
| 140 |
Oestrogen |
- |
- |
- |
- |
[1] 78 |
| 141 |
Omnitrope |
Somatotropin |
D02691 |
[1] GHR |
[5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
[2] 78, 193 |
| 142 |
Omnitrope® |
Somatotropin |
D02691 |
[1] GHR |
[5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
[1] 78 |
| 143 |
Once daily subcutaneous injection of genotropin |
- |
- |
- |
- |
[1] 78 |
| 144 |
Once weekly subcutaneous injection of transcon hgh |
- |
- |
- |
- |
[1] 78 |
| 145 |
Peg-somatropin |
Somatotropin |
D02691 |
[1] GHR |
[5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
[1] 78 |
| 146 |
Pegvisomant |
Pegvisomant |
D05394 |
[1] GHR |
[5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
[1] 78 |
| 147 |
Pegylated polypeptide hormone of human recombinant origin peg-hgh |
- |
- |
- |
- |
[1] 78 |
| 148 |
Pegylated recombinant human growth hormone |
Somatotropin |
D02691 |
[1] GHR |
[5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
[1] 78 |
| 149 |
Pegylated somatropin |
Somatotropin |
D02691 |
[1] GHR |
[5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
[1] 78 |
| 150 |
Pha-794,428 |
- |
- |
- |
- |
[1] 78 |
| 151 |
Pha-794428 |
- |
- |
- |
- |
[1] 78 |
| 152 |
Phosphate |
Phosphate ion |
- |
- |
- |
[29] 2, 3, 11, 12, 13, 28, 36, 46, 49, 51, 53, 60, 62, 65, 70, 78, 81, 83, 90, 96, 97, 164, 235, 256, 283, 284, 285, 286, 299 |
| 153 |
Phosphate sandoz |
Phosphate ion |
- |
- |
- |
[1] 78 |
| 154 |
Pioglitazone |
Pioglitazone |
D00945, D08378 |
[1] PPARG |
[9] AMPK signaling pathway, Huntington disease, Longevity regulating pathway, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer |
[17] 2, 6, 13, 15, 20, 46, 49, 65, 67, 78, 81, 86, 96, 229, 265, 298, 299 |
| 155 |
Plenadren 20 mg modified-release tablets |
- |
- |
- |
- |
[1] 78 |
| 156 |
Plenadren 5 mg modified-release tablets |
- |
- |
- |
- |
[1] 78 |
| 157 |
Pn-180307 |
- |
- |
- |
- |
[1] 78 |
| 158 |
R-hgh |
- |
- |
- |
- |
[1] 78 |
| 159 |
R-hgh freeze-dried |
- |
- |
- |
- |
[1] 78 |
| 160 |
R-hgh liquid (saizen) |
- |
- |
- |
- |
[1] 78 |
| 161 |
Recombinanat dna-derived human growth |
- |
- |
- |
- |
[1] 78 |
| 162 |
Recombinanat dna-derived human growth hormone produced in e.coli |
Somatotropin |
D02691 |
[1] GHR |
[5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
[1] 78 |
| 163 |
Recombinant dna-derived human growth hormone |
Somatotropin |
D02691 |
[1] GHR |
[5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
[1] 78 |
| 164 |
Recombinant dna-derived human growth hormone produced in e.coli |
Somatotropin |
D02691 |
[1] GHR |
[5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
[1] 78 |
| 165 |
Recombinant growth hormone |
Somatotropin |
D02691 |
[1] GHR |
[5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
[2] 78, 96 |
| 166 |
Recombinant growth hormone, genotropin (pfizer) |
Somatotropin |
D02691 |
[1] GHR |
[5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
[1] 78 |
| 167 |
Recombinant human gowth hormone |
- |
- |
- |
- |
[1] 78 |
| 168 |
Recombinant human growth hormone |
Somatotropin |
D02691 |
[1] GHR |
[5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
[3] 78, 193, 265 |
| 169 |
Recombinant human growth hormone (genotropin® ) |
Somatotropin |
D02691 |
[1] GHR |
[5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
[1] 78 |
| 170 |
Recombinant human growth hormone (r-hgh) |
Somatotropin |
D02691 |
[1] GHR |
[5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
[1] 78 |
| 171 |
Recombinant human growth hormone (rhgh) |
Somatotropin |
D02691 |
[1] GHR |
[5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
[1] 78 |
| 172 |
Recombinant human growth hormone(rhgh) |
Somatotropin |
D02691 |
[1] GHR |
[5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
[1] 78 |
| 173 |
Recombinant human igf-1 |
- |
- |
- |
- |
[2] 78, 299 |
| 174 |
Recombinant human serum albumin (hsa) fused to human growth hormone (hgh) |
Human serum albumin |
D05424 |
- |
- |
[1] 78 |
| 175 |
Recombinant human somatotropin |
Somatotropin |
D02691 |
[1] GHR |
[5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
[2] 78, 236 |
| 176 |
Recombinat human growth hormone |
Somatotropin |
D02691 |
[1] GHR |
[5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
[1] 78 |
| 177 |
Regular insulin |
- |
- |
- |
- |
[1] 78 |
| 178 |
Rhgh |
Somatotropin |
D02691 |
[1] GHR |
[5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
[2] 78, 96 |
| 179 |
Routine transdermal oestrogen patch |
- |
- |
- |
- |
[1] 78 |
| 180 |
Rvg 15790 or rvg 25480 |
- |
- |
- |
- |
[1] 78 |
| 181 |
Saizen |
Somatotropin |
D02691 |
[1] GHR |
[5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
[1] 78 |
| 182 |
Saizen 8mg click.easy powder for solution for injection |
Somatotropin |
D02691 |
[1] GHR |
[5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
[1] 78 |
| 183 |
Saizen® |
- |
- |
- |
- |
[1] 78 |
| 184 |
Saline |
Sodium chloride |
D02056 |
- |
- |
[10] 6, 13, 17, 53, 67, 78, 86, 97, 168, 299 |
| 185 |
Sc recombinant growth hormone + amitriptyline, fluoxetine and tramadol (treated group) |
Amitriptyline |
D00809, D07448 |
[2] SLC6A2, SLC6A4 |
[2] Serotonergic synapse, Synaptic vesicle cycle |
[1] 78 |
| 186 |
Serum albumin |
Human serum albumin |
D05424 |
- |
- |
[1] 78 |
| 187 |
Somapacitan |
Somapacitan |
D11194 |
[1] GHR |
[5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
[1] 78 |
| 188 |
Somatorelin |
Somatorelin |
D08523 |
[1] GHRHR |
[2] Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction |
[2] 13, 78 |
| 189 |
Somatostatin |
Somatostatin |
D07431 |
[5] SSTR1, SSTR2, SSTR3, SSTR4, SSTR5 |
[4] Gastric acid secretion, Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
[2] 67, 78 |
| 190 |
Somatotropin |
Somatotropin |
D02691 |
[1] GHR |
[5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
[2] 78, 236 |
| 191 |
Somatotropine |
- |
- |
- |
- |
[1] 78 |
| 192 |
Somatrogon |
Somatrogon |
D10990 |
- |
- |
[1] 78 |
| 193 |
Somatropin |
Somatotropin |
D02691 |
[1] GHR |
[5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
[15] 2, 3, 19, 46, 74, 75, 78, 96, 113, 193, 195, 265, 274, 276, 299 |
| 194 |
Somatropin (rdna origin) |
Somatotropin |
D02691 |
[1] GHR |
[5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
[1] 78 |
| 195 |
Somatropin aq |
Somatotropin |
D02691 |
[1] GHR |
[5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
[1] 78 |
| 196 |
Somatropin for injection |
Somatotropin |
D02691 |
[1] GHR |
[5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
[1] 78 |
| 197 |
Somatropin injection |
Somatotropin |
D02691 |
[1] GHR |
[5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
[1] 78 |
| 198 |
Somatropine |
- |
- |
- |
- |
[1] 78 |
| 199 |
Somavaratan |
Somavaratan |
D11193 |
[1] GHR |
[5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
[1] 78 |
| 200 |
Somavaratan (vrs-317) |
Somavaratan |
D11193 |
[1] GHR |
[5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
[1] 78 |
| 201 |
Strontium ranelate |
Strontium ranelate |
D08468 |
- |
- |
[1] 78 |
| 202 |
Sustained-release recombinant human gh (sr-rhgh) |
Somatotropin |
D02691 |
[1] GHR |
[5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
[1] 78 |
| 203 |
Synacthen |
- |
- |
- |
- |
[1] 78 |
| 204 |
Synacthen (tetracosactrin) |
Tetracosactide |
D00284 |
[1] MC2R |
[5] Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
[1] 78 |
| 205 |
Syntropin |
- |
- |
- |
- |
[1] 78 |
| 206 |
Tesamorelin |
Tesamorelin |
D06655, D09015 |
[1] GHRHR |
[2] Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction |
[2] 78, 265 |
| 207 |
Testogel |
- |
- |
- |
- |
[1] 78 |
| 208 |
Testosterone |
Testosterone |
D00075, D00957, D00958, D00959, D06085, D06087 |
[1] AR |
[3] Oocyte meiosis, Pathways in cancer, Prostate cancer |
[7] 1, 2, 3, 13, 78, 113, 265 |
| 209 |
Testosterone plus somatropin |
Testosterone |
D00075, D00957, D00958, D00959, D06085, D06087 |
[1] AR |
[3] Oocyte meiosis, Pathways in cancer, Prostate cancer |
[1] 78 |
| 210 |
Tetracosactrin |
Tetracosactide |
D00284 |
[1] MC2R |
[5] Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
[1] 78 |
| 211 |
Theraderm |
Levomenthol |
D00064 |
[2] TRPA1, TRPM8 |
[1] Inflammatory mediator regulation of TRP channels |
[1] 78 |
| 212 |
Thyroxin, triiodothyronine |
Liothyronine |
D01011, D08128 |
[2] THRA, THRB |
[2] Neuroactive ligand-receptor interaction, Thyroid hormone signaling pathway |
[1] 78 |
| 213 |
Tramadol |
Tramadol |
D01355, D08623 |
[1] OPRM1 |
[3] Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction |
[5] 46, 70, 78, 226, 271 |
| 214 |
Transcon hgh |
- |
- |
- |
- |
[1] 78 |
| 215 |
Transdermal testosterone gel |
Testosterone |
D00075, D00957, D00958, D00959, D06085, D06087 |
[1] AR |
[3] Oocyte meiosis, Pathways in cancer, Prostate cancer |
[1] 78 |
| 216 |
Transiently pegylated hgh prodrug |
- |
- |
- |
- |
[1] 78 |
| 217 |
Triiodothyronine |
Liothyronine |
D01011, D08128 |
[2] THRA, THRB |
[2] Neuroactive ligand-receptor interaction, Thyroid hormone signaling pathway |
[1] 78 |
| 218 |
Trisequens |
- |
- |
- |
- |
[1] 78 |
| 219 |
Tv-1106 |
- |
- |
- |
- |
[1] 78 |
| 220 |
Tv1106 |
- |
- |
- |
- |
[1] 78 |
| 221 |
Vrs-317 |
- |
- |
- |
- |
[1] 78 |
| 222 |
Zomacton |
Somatotropin |
D02691 |
[1] GHR |
[5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
[1] 78 |